Where aches stand in the Ozempic® documents
The three regulators’ documents were checked on 20 October 2026. None has a musculoskeletal row. The closest items are the injection site reactions, which are local, and the Canadian fatigue row, which also counts weakness (asthenia).
| Document | Muscle, joint or back pain | Closest listed items |
|---|---|---|
| US Prescribing Information, revised 05/2026 [1] | Not listed | Injection site reactions such as discomfort or redness in 0.2% of people in placebo-controlled trials |
| EU summary of product characteristics, section 4.8 [2] | Not listed | Injection site reactions: uncommon; fatigue: common |
| Canadian monograph, Table 2 [3] | Not listed | Fatigue and asthenia combined: comparator 1.4%, 0.5 mg 2.6%, 1 mg 3.3% |
What trial analyses and cohorts report
A 2026 systematic review and meta-analysis combined 43 randomised trials of GLP-1-based medicines with 100,488 participants. It found no significant difference from control groups in reported gouty arthritis, rheumatoid arthritis, osteoarthritis, osteoporotic fractures, synovitis or spinal disc protrusion [4]. These were adverse events reported in the trials rather than conditions searched for systematically, which is a limitation the design cannot avoid.
For gout specifically, a 2024 network meta-analysis of 22 placebo-controlled outcome trials with 173,498 patients found GLP-1 medicines had no significant effect on gout risk, unlike SGLT2 inhibitors, which lowered it [5].
Observational data are less reassuring. A 2025 Nature Medicine study of US veterans with diabetes associated GLP-1 use with a higher risk of arthritic disorders than continued usual care [6]. Because people starting GLP-1 medicines may differ in many ways from those who do not, this association does not show that the medicine causes joint problems.
Why someone on Ozempic® might ache
From the label: low blood sugar, which section 5.5 links to combining Ozempic® with a sulfonylurea or insulin, can show up as weakness and shakiness [1]. Dehydration after vomiting or diarrhoea is a separate label warning [1]. MedlinePlus counts low potassium or calcium levels, an electrolyte imbalance, among possible causes of muscle pain, and advises drinking fluids around exercise [8].
Proposed and partly studied: losing muscle along with fat. A 2025 review reports that lean body mass can account for roughly 15% to 40% of the weight lost on GLP-1 medicines, and says evidence in older adults and people with kidney or liver disease is still limited [7]. Muscle loss is not the same as pain, but weaker muscles can make everyday effort feel harder.
General background: starting a new exercise routine alongside treatment, which many people do, is itself a common source of soreness. MedlinePlus lists overuse, too much too soon, and skipping a warm-up among the most common causes of muscle aches [8].
Other common causes
Most aches have ordinary explanations. MedlinePlus lists, among others [8][9]:
- Injury, strains, sprains and overuse; tension and stress.
- Medicines including statins for cholesterol and ACE inhibitors for blood pressure.
- Viral infections such as flu, and other infections.
- Arthritis, including osteoarthritis, rheumatoid arthritis and gout, as well as bursitis and tendinitis.
- Fibromyalgia, lupus and polymyalgia rheumatica.
- Less commonly, muscle breakdown (rhabdomyolysis).
What general sources suggest
For aches from overuse or minor injury, MedlinePlus describes resting the area, ice in the first days and heat afterwards, gentle stretching, massage, enough sleep and stress reduction [8]. It suggests warming up and cooling down around exercise, stretching through long periods at a desk, and building up activity gradually. For joint pain that is not from arthritis, it describes rest balanced with exercise, warm baths and stretching [9]. If you are considering a pain reliever, ask your pharmacist which one fits with Ozempic® and your other medicines.
On muscle loss, the 2025 review suggests that protein-focused eating and resistance training may help preserve muscle during GLP-1 treatment, tailored to the person [7]. How that applies to you is a question for your clinician or a dietitian.
Ozempic® context
Ozempic® is a weekly injection for adults with type 2 diabetes; the label starts at 0.25 mg and raises the dose after at least four weeks at each step [1]. The injection goes into the fatty tissue of the abdomen, thigh or upper arm, and local discomfort at the site is a listed but uncommon reaction [1][2]. Section 5.2 warns about pancreatitis, whose pain can spread from the stomach to the back [1]; back pain together with severe stomach pain should not be treated as an ordinary ache.
Ozempic® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Aches with passing less urine, sudden weight gain or fluid retention
Contact: Emergency services
MedlinePlus [8]
- Muscle weakness or being unable to move part of the body, shortness of breath or difficulty swallowing
Contact: Emergency services
MedlinePlus [8]
- Aches with vomiting, a very stiff neck or a high fever
Contact: Emergency services
MedlinePlus [8]
- Severe stomach pain that will not go away and spreads to the back
Contact: Stop Ozempic® and contact your provider right away, as the Medication Guide says for possible pancreatitis
Ozempic® Medication Guide [1]
Today
- Weakness with shakiness, sweating or confusion, especially with a sulfonylurea or insulin
Contact: Treat low blood sugar as your care team has shown you, then call your prescriber
Ozempic® Medication Guide [1]